Insider Sale at Entrada Therapeutics Inc by President of Research Development - GuruFocus.com
TRDA Stock | USD 19.89 0.06 0.30% |
About 66% of Entrada Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Entrada Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Entrada Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Entrada Therapeutics stock news signals to limit their universe of possible portfolio assets.
Entrada |
Insider Sale at Entrada Therapeutics Inc by President of Research Development GuruFocus.com
Read at news.google.com
Entrada Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Entrada Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Entrada Therapeutics Fundamental Analysis
We analyze Entrada Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entrada Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entrada Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Entrada Therapeutics is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Entrada Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Entrada Therapeutics stock to make a market-neutral strategy. Peer analysis of Entrada Therapeutics could also be used in its relative valuation, which is a method of valuing Entrada Therapeutics by comparing valuation metrics with similar companies.
Peers
Entrada Therapeutics Related Equities
GLUE | Monte Rosa | 13.72 | ||||
OPT | Opthea | 10.81 | ||||
VIGL | Vigil Neuroscience | 7.39 | ||||
RLYB | Rallybio Corp | 6.36 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
EWTX | Edgewise Therapeutics | 2.48 | ||||
CNTA | Centessa Pharmaceuticals | 1.76 | ||||
PMVP | Pmv Pharmaceuticals | 1.25 | ||||
MOLN | Molecular Partners | 0.17 | ||||
CRNX | Crinetics Pharmaceuticals | 0.81 | ||||
PEPG | PepGen | 0.98 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
IRON | Disc Medicine | 1.70 | ||||
TYRA | Tyra Biosciences | 2.00 | ||||
PHVS | Pharvaris | 2.06 | ||||
THRD | Third Harmonic | 2.67 | ||||
GNTA | Genenta Science | 3.35 | ||||
LRMR | Larimar Therapeutics | 4.67 |
Complementary Tools for Entrada Stock analysis
When running Entrada Therapeutics' price analysis, check to measure Entrada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entrada Therapeutics is operating at the current time. Most of Entrada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Entrada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entrada Therapeutics' price. Additionally, you may evaluate how the addition of Entrada Therapeutics to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Bonds Directory Find actively traded corporate debentures issued by US companies |